Masnec S, Kokot A, Kralj T et al. · Pharmaceuticals (Basel, Switzerland) · PMID 41471311
From the original abstract
“Taken together, these findings advance cytoprotection as a unifying therapeutic paradigm, with BPC 157 emerging as its first exemplar, and encourage further translational research toward…”
From the closing sentence of the indexed abstract. This is a shortened quotation; the full sentence continues in the original abstract.
Read the full abstract & conclusionThis paper brings together existing research. Its conclusions depend on the included studies and their methods; it is not a separate treatment trial.
A brief excerpt cannot capture the complete methods, results, adverse events, or limitations. Check the full abstract and original paper before interpreting the finding.
Educational research information. A publication does not verify the identity, quality, or safety of products sold here.
Back to BPC-157 studies